India · Delayed Price · Currency is INR Beryl Drugs Statistics
Total Valuation
Beryl Drugs has a market cap or net worth of INR 111.32 million. The enterprise value is 153.67 million.
| Market Cap | 111.32M |
| Enterprise Value | 153.67M |
Important Dates
The last earnings date was Monday, February 9, 2026.
| Earnings Date | Feb 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Beryl Drugs has 5.07 million shares outstanding. The number of shares has increased by 0.08% in one year.
| Current Share Class | 5.07M |
| Shares Outstanding | 5.07M |
| Shares Change (YoY) | +0.08% |
| Shares Change (QoQ) | +14.20% |
| Owned by Insiders (%) | 40.30% |
| Owned by Institutions (%) | n/a |
| Float | 3.03M |
Valuation Ratios
The trailing PE ratio is 789.53.
| PE Ratio | 789.53 |
| Forward PE | n/a |
| PS Ratio | 0.63 |
| PB Ratio | 1.18 |
| P/TBV Ratio | 1.18 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 1,089.85 |
| EV / Sales | 0.87 |
| EV / EBITDA | 10.69 |
| EV / EBIT | 97.44 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.45 |
| Debt / EBITDA | 2.99 |
| Debt / FCF | n/a |
| Interest Coverage | 0.46 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 1.15% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 4.73% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.90M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.93% in the last 52 weeks. The beta is -0.02, so Beryl Drugs's price volatility has been lower than the market average.
| Beta (5Y) | -0.02 |
| 52-Week Price Change | -30.93% |
| 50-Day Moving Average | 22.41 |
| 200-Day Moving Average | 21.88 |
| Relative Strength Index (RSI) | 48.05 |
| Average Volume (20 Days) | 1,924 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Beryl Drugs had revenue of INR 176.65 million and earned 141,000 in profits. Earnings per share was 0.03.
| Revenue | 176.65M |
| Gross Profit | 77.66M |
| Operating Income | 1.58M |
| Pretax Income | -1.76M |
| Net Income | 141,000 |
| EBITDA | 14.37M |
| EBIT | 1.58M |
| Earnings Per Share (EPS) | 0.03 |
Balance Sheet
The company has 668,000 in cash and 43.01 million in debt, with a net cash position of -42.35 million or -8.35 per share.
| Cash & Cash Equivalents | 668,000 |
| Total Debt | 43.01M |
| Net Cash | -42.35M |
| Net Cash Per Share | -8.35 |
| Equity (Book Value) | 94.69M |
| Book Value Per Share | 21.28 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 43.96%, with operating and profit margins of 0.89% and 0.08%.
| Gross Margin | 43.96% |
| Operating Margin | 0.89% |
| Pretax Margin | -1.00% |
| Profit Margin | 0.08% |
| EBITDA Margin | 8.14% |
| EBIT Margin | 0.89% |
| FCF Margin | n/a |
Dividends & Yields
Beryl Drugs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.08% |
| Shareholder Yield | -0.08% |
| Earnings Yield | 0.13% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |